메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

MindHYVE.ai™ and KPSIAJ Sign Strategic MOU to Advance AI-Driven Innovation in Education and Healthcare Across Karachi

KARACHI, Pakistan, Dec. 23, 2025 -- MindHYVE.ai, Inc., and Khoja (Pirhai) Shia Isna Asheri Jamaat (KPSIAJ) announced the signing of a landmark Memorandum of Understanding (MOU) establishing a strategic collaboration to introduce responsible, community-centered AI innovation across KPSIAJ's education and healthcare ecosystem. Under this agreement, MindHYVE.ai™ will support KPSIAJ in deploying its proprietary agentic AI platforms, ArthurAI™ for adaptive learning and ChironAI™ for clinical decision-support readiness evaluations, across the Fatimiyah Education Network (FEN), Fatimi
- 김갑성 기자
- 2025-12-23 07:30
Temu Signs Australian Equipment Safety Pledge to Enhance Consumer Protection

SYDNEY, Dec. 23, 2025 -- Temu has joined the Australian Communications and Media Authority (ACMA)'s Equipment Safety Pledge, a new voluntary initiative aimed at strengthening consumer protections and reduce the availability of unsafe or illegal communications devices sold online. Temu is among the founding signatories of the pledge, alongside other major e-commerce platforms, reflecting a shared commitment to consumer safety and regulatory compliance in Australia. Announced by the ACMA in December 2025, the pledge outlines a series of voluntary commitments aimed at helping prevent the
- 김갑성 기자
- 2025-12-23 07:00
TraceLink Wins 2025 Merit Award -- Recognized for Healthcare Innovation for the Third Consecutive Year

TraceLink has been named a winner of the 2025 Merit Awards for Healthcare Innovation, marking its third consecutive year of recognition. The award honors TraceLink's continued leadership in transforming the life sciences and healthcare supply chain through OPUS—its industrial no-code platform that powers agentic supply chain orchestration across a global network of more than 310,000 authenticated partners. BOSTON, Dec. 22, 2025 -- TraceLink, the world's largest end-to-end digital network platform for intelligent supply chain orchestration, today announced that it has been named
- 김갑성 기자
- 2025-12-22 23:00
MCB Group Unveils Daily Sports Nutrition Innovations at SupplySide Global 2025, Spotlighting Creatine, MCT, and Plant-Based Protein

TAIPEI, Dec. 22, 2025 -- MCB Group, a Taiwan-based global manufacturer of premium nutritional powder ingredients, has further streamlined its operations into a full CDMO private-label provider, showcasing a range of trend-driven branded ingredients and turnkey total solutions at SupplySide Global 2025, aimed at capturing growth in next year's booming market. The focus on MCB's new ingredients reflects insights generated through its AI-powered market platform, revealing a clear shift: sports nutrition is rapidly becoming part of everyday nutrition. Consumers now prefer convenien
- 김갑성 기자
- 2025-12-22 22:00
AI Platform to Combat Muscle Loss and Preserve Metabolic Vitality for GLP-1 Users

Livelively USA combines AI insights with Eastern wellness principles to support healthier long-term weight management behaviors. NEW YORK, Dec. 22, 2025 -- Weight-loss medications are reshaping global healthcare, with the anti-obesity drug market projected to approach $100 billion by 2030, according to Goldman Sachs. As millions begin GLP-1 therapy, interest is growing around how to maintain strength, vitality, and well-being throughout treatment. Livelively USA Inc. today introduced a metabolic wellness platform that integrates predictive AI with Integrative Longevity S
- 김갑성 기자
- 2025-12-22 21:00
Kazia Therapeutics Regains Full Nasdaq Listing Compliance

[ 메디채널 황정호 기자 ] Restoration of Nasdaq compliance follows $50 million institutional financing and reinforces balance-sheet strength SYDNEY, Dec. 22, 2025 -- Kazia Therapeutics Limited ("Kazia" or the "Company") (NASDAQ: KZIA), a clinical-stage oncology company focused on developing innovative therapies for cancer, today announced that it has regained full compliance with all applicable listing standards of Nasdaq. On December 18, 2025, the Company received written notification from Nasdaq confirming that Kazia has regained compliance with Nasdaq Listing Rule
- 황정호 기자
- 2025-12-22 21:00
Yii Partners with Japan's ANDS Corporation: Building Skin Resilience through Pharmaceutical-Grade Science

HONG KONG, Dec. 22, 2025 -- Japanese skincare brand Yii is collaborating with ANDS Corporation (hereinafter "ANDS"), an affiliate of Rohto Pharmaceutical Co., Ltd., to explore the niche skincare market with pharmaceutical-grade scientific excellence. The collaboration combines over 60 years of ANDS's formulation expertise with Yii's Eastern philosophy of "Nourish effortless beauty," delivering proven efficacy and high safety for sensitive, barrier-compromised, and early-aging skin types. Where Eastern Philosophy Meets Japanese Craftsmanship Modern lifestyles,
- 김갑성 기자
- 2025-12-22 17:51
Menarini Silicon Biosystems announces PACE trial biomarker analysis results confirming clinical utility of CELLSEARCH® CTC enumeration to guide treatment decisions in a specific metastatic breast cancer subtype

The secondary analysis of the PACE trial highlights the value of counting Circulating Tumor Cells (CTCs) in the blood to help guide treatment escalation or de-escalation in patients with hormone receptor-positive (HR+), HER2-negative (HER2-) metastatic breast cancer whose disease progressed after treatment with aromatase inhibitors plus CDK4/6 inhibitors. CTC count is a standalone predictive biomarker, independent of clinical risk factors and circulating tumor DNA. BOLOGNA, Italy and HUNTINGDON VALLEY, Pa., Dec. 22, 2025 -- Menarini Silicon Biosystems, a pioneer of cell-based l
- 김갑성 기자
- 2025-12-22 16:00
Guardant Health Japan receives regulatory approval of Guardant360® CDx liquid biopsy as companion diagnostic for imlunestrant in metastatic or recurrent breast cancer previously treated with endocrine therapy

[ 메디채널 김갑성 기자 ] Guardant360® CDx is the first companion diagnostic to be approved in Japan to identify ESR1 mutations in patients with hormone receptor-positive, HER2-negative breast cancer for treatment with imlunestrant TOKYO, Dec. 22, 2025 -- Guardant Health Japan Corp. today announced that the Ministry of Health, Labour and Welfare (MHLW) has approved Guardant360® CDx on 23 October 2025 as a companion diagnostic to identify ESR1 mutations in patients with hormone receptor–positive, HER2-negative breast cancer with disease progression following endocrine therapy, for consi
- 김갑성 기자
- 2025-12-22 16:00
OK Biotech Recognized at International Innovation Awards (IIA) 2025 for OTC Hearing Aid Innovation

SHANGHAI, Dec. 22, 2025 -- OK Biotech Co., Ltd. has been honoured at the International Innovation Awards (IIA) 2025, organized by Enterprise Asia, for its development of the OKB OTC Hearing Aid, a device designed to improve comfort and sound clarity for adults with hearing loss. The OKB OTC Hearing Aid was created from personal experience, with the company's Chairman—who has lived with hearing impairment—personally leading its development. The device addresses common challenges with traditional hearing aids, focusing on ease of use, comfort, and effective sound capture for daily activi
- 황정호 기자
- 2025-12-22 14:46

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2026-01-01_THU

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2026년 01월 01일 16시 00분